News & Press Releases

Year

Feb 27, 2023

Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden

BOSTON and LONDON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with the New Therapies (NT) Council which will result in reimbursed access to Libmeldy ® (atidarsagene autotemcel) for all

Feb 24, 2023

Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™

Administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 11 years of follow-up (median 6.15 years) Composite primary endpoint used in analysis was developed through ongoing discussions with the U.S.

Feb 10, 2023

Orchard Therapeutics Announces Proposed ADS Ratio Change

BOSTON and LONDON, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares (the "ADS Ratio"), nominal value £0.10 per share, from the

Feb 08, 2023

Orchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLDSymposium

Four oral presentations and 11 posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic diseases BOSTON and LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced a

Jan 09, 2023

Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones

Libmeldy ® revenue totaled $5.8M in Q4 2022 and $18.8M for the full year with commercial expansion activities continuing in Europe Clinical Type B meeting with U.S. FDA to take place in early 2023 prior to OTL-200 (MLD) BLA submission Ended 2022 with approximately $144M in cash and investments and

Jan 05, 2023

Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH

Global registrational trial expected to commence in the second half of 2023 BOSTON and LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug

First page
Previous page
Page 1
Current page 2

Investors & Media

News & Press Releases

News & Press Releases

News & Press Releases